This highlights a need to sub-categorise ptgs2 expression in CRC tumours such that low marker tumours are delineated from high marker tumours and also from those in which the marker is absent or undetected, and testing their prognostic relationships in future study designs. This evidence concerns the gene PTGS2 and neoplasm.